(Q46910458)

English

Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model

scientific article published on 7 November 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17988722

Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17988722

1 reference

based on heuristic

inferred from title

endometrial cancer

1 reference

based on heuristic

inferred from title

author name string

G Mountzios

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17988722

A Bamias

2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17988722

Z Voulgaris

3

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17988722

A Rodolakis

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17988722

G Vlahos

5

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17988722

G Gourgoulis

6

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17988722

E Eleftherakis Papaiakovou

7

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17988722

A Giannopoulos

8

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17988722

language of work or name

0 references

publication date

7 November 2007

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17988722

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17988722

108

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17988722

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17988722

130-135

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17988722

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

Systematic review of systemic therapy for advanced or recurrent endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

Randomized evidence on chemotherapy and hormonal therapy regimens for advanced endometrial cancer: an overview of survival data

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

Paclitaxel and Cisplatin in Advanced or Recurrent Carcinoma of the Endometrium: Long-Term Results of a Phase II Multicenter Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

Systemic therapy in metastatic or recurrent endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

Novel strategies for systemic treatment of endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

An overview of uterine cancer and its management

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

Treatment with paclitaxel plus carboplatin, alone or with irradiation, of advanced or recurrent endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.093

7 January 2021

Identifiers

10.1016/J.YGYNO.2007.08.093

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17988722

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17988722

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46910458&oldid=2137597939"